AlphAIalphai — Financial news for AI agents
fool.comAUG 187 min read$HIMS

Hims (HIMS) Q2 2026 Earnings Call Transcript

Hims & Hers Health (HIMS) reported Q2 2026 revenue of $753.2M (+38% YoY) and 2.891M subscribers (+19%). Net loss was $86.3M, including $81M nonrecurring costs. Adjusted EBITDA was $60.3M (8% margin). Gross margin fell to 64%. Full-year 2026 revenue guidance raised to $3.1B-$3.3B.

Original reporting
fool.com
Published Aug 18, 2026, 12:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 1:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Hims (HIMS) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$HIMSBullishMed
01

Why it matters

Traders can update models based on the raised full-year and Q3 revenue and adjusted EBITDA guidance, while monitoring gross margin trajectory, cash flow, and the FTC contingency accrual.

02

Market read

The article provides fresh, decision-relevant guidance numbers and balance-sheet/liquidity actions (receivables facility and convertible debt) that can drive near-term estimate revisions.

03

What to watch

The FTC-related legal contingency accrual and the receivables facility terms could become incremental overhangs if regulatory outcomes or liquidity costs worsen.

Relevance 9/10Novelty 8/10Timing: pre-market/next-session positioning after the Aug. 10 earnings call transcript

Background

This is a transcript-style summary of Hims & Hers’ Q2 2026 earnings call, including financial results, guidance, acquisition contribution, and regulatory/legal commentary.

Company-level read

Ticker impact

$HIMSBullishMedium confidence
Context

Hims & Hers reported Q2 results and raised 2026 revenue guidance to $3.1B-$3.3B, plus Q3 revenue $880M-$900M.

Expected impact

Bias toward upward estimate revisions, with volatility around margin and cash flow commentary.

Evidence & confidence

The article discloses multiple forward-looking datapoints (raised full-year and Q3 guidance, international growth expectations) alongside persistent margin pressure and legal contingency accrual.

Market effects

Sector

Reinforces competitive intensity in GLP-1 and branded weight loss, with margin pressure tied to mix shift and international scaling.

Regional

Highlights UK, Australia, and Germany as major growth engines, potentially affecting regional consumer health and telehealth sentiment.

Global

International revenue scaling and acquisition integration (Eucalyptus) may influence how investors underwrite cross-border telehealth expansion.

Counterpoint

What could challenge this read

Raised revenue guidance may not translate into improved profitability if gross margin compression persists and working-capital needs keep operating cash flow negative.

Key entities

  • company
    Hims & Hers Health, Inc.

    Telehealth and specialty pharmacy provider reporting Q2 2026 results, raised 2026 guidance, and discussing margin, cash flow, and FTC-related legal contingency.

  • acquired business
    Eucalyptus

    Australia-based healthcare technology platform acquired in June 2026, contributing $40M revenue in the quarter.

  • regulator
    Federal Trade Commission (FTC)

    Referenced via a $47.5M legal contingency accrual tied to terms the company says it could not accept.

  • partner
    Novo Nordisk

    Referenced as a partnership facilitating access to Wegovy treatment.

Read at source← All news

Related articles

AUG 17
$HIMSMed

5 Revealing Analyst Questions From Hims & Hers Health’s Q2 Earnings Call

Hims & Hers Health reported Q2 revenue of $753.2M versus $699M estimates and adjusted EBITDA of $60.32M versus $47.26M, but adjusted EPS was -$0.09 versus $0.11. The company lifted full-year revenue guidance to $3.2B and EBITDA guidance to $300M midpoint. Shares fell over 5% amid higher operating expenses and litigation costs, while management cited AI-driven customer acquisition and Eucalyptus integration.

financialcontent.com6 min
AUG 15
$HIMSMed

HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership

Hims & Hers Health (HIMS) rose about 6% intraday before closing up 1.33% after Barclays upgraded its outlook. Barclays raised its HIMS price target to $39 from $29 and kept an Overweight rating, citing accelerating growth tied to Hims & Hers’ Novo Nordisk (NVO) partnership announced March 9. Barclays expects revenue and EBITDA acceleration in 2H 2026.

stocktwits.com3 min
AUG 12
$HIMSMed

NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

Kessler Topaz Meltzer & Check said it is investigating potential federal securities-law violations by Hims & Hers Health, Inc. (NYSE: HIMS) after the FTC filed a July 29, 2026 lawsuit alleging the company shared customers’ medical information with third-party advertisers including Snap and Meta’s Facebook. HIMS shares reportedly fell more than 14% after the news.

prnewswire.com3 min